Alps Advisors Inc Chinook Therapeutics, Inc. Transaction History

Alps Advisors Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$18.66 - $38.58 $107,966 - $223,223	5,786 Added 13.34%	49,166 $1.89 Million
Q1 2023 May 10, 2023	BUY	$21.53 - $26.8 $839 - $1,045	39 Added 0.09%	43,380 $1 Million
Q4 2022 Feb 14, 2023	BUY	$18.63 - $27.35 $168,284 - $247,052	9,033 Added 26.33%	43,341 $1.14 Million
Q3 2022 Nov 14, 2022	SELL	$17.51 - $23.37 $38,522 - $51,414	-2,200 Reduced 6.03%	34,308 $674,000
Q2 2022 Aug 11, 2022	SELL	$12.59 - $18.8 $224,807 - $335,692	-17,856 Reduced 32.85%	36,508 $639,000
Q1 2022 May 16, 2022	SELL	$12.02 - $16.69 $82,421 - $114,443	-6,857 Reduced 11.2%	54,364 $889,000
Q4 2021 Feb 09, 2022	BUY	$10.69 - $16.83 $67,539 - $106,331	6,318 Added 11.51%	61,221 $999,000
Q3 2021 Nov 15, 2021	SELL	$11.5 - $14.86 $44,367 - $57,329	-3,858 Reduced 6.57%	54,903 $701,000
Q2 2021 Aug 11, 2021	SELL	$13.6 - $18.98 $238,040 - $332,206	-17,503 Reduced 22.95%	58,761 $830,000
Q1 2021 May 07, 2021	BUY	$14.17 - $19.11 $670,566 - $904,342	47,323 Added 163.52%	76,264 $1.19 Million
Q4 2020 Feb 03, 2021	BUY	$11.9 - $20.91 $344,397 - $605,156	28,941 New	28,941 $459,000

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.